Home - Products - Others - Other Targets - (E)-3-(Naphth-1-yl)acrylic acid

(E)-3-(Naphth-1-yl)acrylic acid

CAS No. 2006-14-6

(E)-3-(Naphth-1-yl)acrylic acid( —— )

Catalog No. M37046 CAS No. 2006-14-6

(E)-3-(Naphth-1-yl)acrylic acid (3-(1-Naphthyl)acrylic acid) is a biochemical reagent that can be used to synthesize a variety of compounds and participate in many reactions in the body.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 27 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (E)-3-(Naphth-1-yl)acrylic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    (E)-3-(Naphth-1-yl)acrylic acid (3-(1-Naphthyl)acrylic acid) is a biochemical reagent that can be used to synthesize a variety of compounds and participate in many reactions in the body.
  • Description
    (E)-3-(Naphth-1-yl)acrylic acid (3-(1-Naphthyl)acrylic acid) is a biochemical reagent that can be used to synthesize a variety of compounds and participate in many reactions in the body.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2006-14-6
  • Formula Weight
    198.22
  • Molecular Formula
    C13H10O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(=C/C(O)=O)\C=1C2=C(C=CC1)C=CC=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Pomalidomide-PEG2-OH

    Pomalidomide-PEG2-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.

  • Nimorazole

    Nimorazole is a nitroimidazole anti-infective.

  • KIRA6

    KIRA6 is an effective inhibitor of IRE1α RNase kinase (IC50: 0.6 μM). It can trigger an apoptotic response.KIRA6 (10-1000 nM, 72 hours) strongly compromises the viability of the KIT-dependent cell line HMC-1.1 at the low nM concentration, in a manner that coincided with KIT blockade.